<SEC-DOCUMENT>0001213809-20-000014.txt : 20200225
<SEC-HEADER>0001213809-20-000014.hdr.sgml : 20200225
<ACCEPTANCE-DATETIME>20200225145335
ACCESSION NUMBER:		0001213809-20-000014
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200225
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200225
DATE AS OF CHANGE:		20200225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYADIC INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001213809
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				450486747
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32513
		FILM NUMBER:		20650086

	BUSINESS ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477
		BUSINESS PHONE:		561-743-8333

	MAIL ADDRESS:	
		STREET 1:		140 INTRACOASTAL POINTE DRIVE
		STREET 2:		SUITE 404
		CITY:			JUPITER
		STATE:			FL
		ZIP:			33477

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CCP WORLDWIDE INC
		DATE OF NAME CHANGE:	20030110
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8-kiibrxfebruary252020.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie6413037fb83404485b7e6ac0aa9a754_1"></div><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%;">UNITED STATES</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center;margin-bottom:7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:30.958%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.083%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.959%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:9pt;margin-bottom:7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%;">FORM 8-K</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:30.958%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.083%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.959%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">CURRENT REPORT</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">Pursuant to Section 13 or 15(d) of the</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">Securities Exchange Act of 1934</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Date of Report (date of earliest event reported)&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration: underline;">February 25, 2020</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:30.958%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.083%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.959%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;margin-top:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:173%;">Dyadic International, Inc.</font></div><div style="text-align:center;margin-bottom:7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Exact name of registrant as specified in its charter)</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:30.958%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.083%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.959%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:30.958%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:32.083%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:30.959%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">Delaware</font></div><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%;">(State or other jurisdiction of incorporation or organization)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">000-55264</font></div><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%;">(Commission File Number)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">45-0486747</font></div><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%;">(I.R.S. Employer Identification Number)</font></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">140 Intracoastal Pointe Drive, Suite 404<br>Jupiter, FL 33477</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of principal executive offices and zip code)</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(561) 743-8333</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Registrant&#8217;s telephone number, including area code)</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">N&#47;A</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;"><font><br></font></div><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><font><br></font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="margin-top:15pt;margin-bottom:7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:144%;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions&#58;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:4.973%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:91.027%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#168;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#168;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#168;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#168;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).<br><br></font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:2.25pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company &#9744;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</font></td></tr></table></div><div style="margin-top:9pt;margin-bottom:13pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:9pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.679%;"><tr><td style="width:1.0%;"></td><td style="width:37.228%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.774%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.998%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Title of each class</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Trading Symbol(s)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Name of each exchange on which registered</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Common Stock, par value $0.001 per share</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">DYAI</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="padding-left:2.25pt;padding-right:2.25pt;text-align:center;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">The NASDAQ Stock Market LLC</font></div></td></tr></table></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Item 8.01 Other Events</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On February 25, 2020, Dyadic International, Inc. (the &#8220;Company&#8221;) announced that they are joining the global fight against the coronavirus outbreak by collaborating with The Israel Institute for Biological Research (&#34;IIBR&#34;), a governmental research institute established to provide the State of Israel with scientific response to chemical and biological threats.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%;">A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</font></div><div style="text-align:justify;"><font><br></font></div><div><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:22.198%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.601%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:73.001%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 9.01  Financial Statements and Exhibits</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><br>(d)  Exhibits<br><br></font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">The following exhibit is being furnished herein&#58;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">Exhibit</font></div><div style="padding-right:2.25pt;text-align:center;margin-top:2pt;margin-bottom:2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;text-decoration: underline;">Number</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);text-decoration: underline;">Description</font></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">99.1</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a href="ex991iibr.htm" style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;">Press Release dated as of February 25, 2020</a></font></div></td></tr></table></div><div style="margin-top:5pt;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">SIGNATURE</font></div><div style="text-align:center;"><font><br></font></div><div style="text-indent:36pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">Date&#58; February 25, 2020</font></div><div style="text-align:right;margin-bottom:7pt;"><font><br></font></div><div style="text-align:right;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:39.262%;"><tr><td style="width:1.0%;"></td><td style="width:19.224%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:76.776%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dyadic International, Inc.</font></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Mark A. Emalfarb</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mark A. Emalfarb</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr></table></div><div style="margin-top:3pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991iibr.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i2728026f564e4e41adc67a1fd453a835_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div><img alt="image01.jpg" src="image01.jpg" style="height:60px;width:76px;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:115%;">Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:#ffffff;color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Nes &#8211; Ziona, ISRAEL and JUPITER, FL &#47; ACCESSWIRE &#47; February 25, 2020</font><font style="background-color:#ffffff;color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> &#47; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Dyadic International, Inc. (''Dyadic'') (NASDAQ&#58; DYAI), a global  biotechnology company announced today that they are joining the global fight against the coronavirus outbreak by collaborating with The Israel Institute for Biological Research (&#8220;IIBR&#8221;), a governmental research institute established to provide the State of Israel with scientific response to chemical and biological threats.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus). </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">The research collaboration combines IIBR&#8217;s renowned scientific capabilities and cGMP facilities with Dyadic&#8217;s patented and proprietary C1 gene expression platform known to shorten the development cycle, lower the manufacturing cost and improve the performance of vaccines and mAbs.</font><font style="background-color:rgb(255,255,255, 0.0);color:#c00000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8220;Our collaboration with the IIBR is aimed at finding additional solutions to combat the COVID-19 coronavirus outbreak that threathens the lives of people in China and globally,&#8221; commented Mark A. Emalfarb, Founder and CEO of Dyadic. &#8220;There is a global need to apply new platforms and technologies that will facilitate a fast, coordinated and practical response to new infectious diseases during pandemic and epidemic outbreaks or a bioterrorist attack and we believe that Dyadic&#8217;s C1 technology is well-positioned to contribute to this global effort.&#8221;  </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8220;Certain data and results generated from this collaboration are expected to futher validate the versatility and safety of our C1 gene expression platform,&#8221; said Dr. Ronen Tchelet, Dyadic&#8217;s Chief Scientific Officer.  </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">&#8220;The Israel Institute for Biologcal Research was assigned by the Israeli Prime minister, Mr. Benjamin Netanyahu, to act as quickly as possible to produce a vaccine and neutralizing antibodies for the Novel Coronavirus COVID-19,&#8221; said Prof. Shmuel C. Shapira, Director General of IIBR. Prof Shapira continued, &#8220;More than 50 experienced Ph.D. IIBR&#8217;s scientists are working tirelessly to produce a vaccine and neutralizing antibodies for the Novel Coronavirus COVID-19. This is a world-leading group in aspect of knowledge, experience and infrastructure. </font><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">The Israel Institute for biological research was assigned to the task based on its proven professional scientific capabilities and previous successes in the field.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">About Israel Institute for Biological Research</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">The Israel Institute for Biological Research (IIBR) is a national center for research and development that specializes in the fields of biology, chemistry and the environmental sciences, </font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#333333;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">and aims to enhance Israel&#8217;s strengths and fortitude.  IIBR recruits leading Israeli scientists and benefits from cutting edge technologies and infrastructure built to serve the topmost research and strict safety standards.  IIBR capabilities, scientific achievements and decades of advanced R&#38;D lead to national and international reputation and prestigious collaborations.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">https&#58;&#47;&#47;iibr.gov.il&#47;Pages&#47;home.aspx</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">About Dyadic International, Inc.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and&#47;or biobetters, and other therapeutic proteins. Additionally, and more recently, Dyadic is also beginning to explore the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly save lives.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Please visit Dyadic&#8217;s website at http&#58;&#47;&#47;www.dyadic.com for additional information, including details regarding Dyadic&#8217;s plans for its biopharmaceutical business.</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Safe Harbor Regarding Forward-Looking Statements</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic International&#8217;s expectations, intentions, strategies and beliefs pertaining to future events or future financial performance.  Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in the Company&#8217;s most recent filings with the SEC. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise.  For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled &#8220;Risk Factors&#8221; in Dyadic&#8217;s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic&#8217;s periodic filings with the SEC, which are accessible on the SEC&#8217;s website at http&#58;&#47;&#47;www.dyadic.com</font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Contact&#58;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Dyadic International, Inc.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Mark Emalfarb, CEO</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Phone&#58; +1 (561) 743-8333</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">Email&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0563c1;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">memalfarb&#64;dyadic.com</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image01.jpg
<TEXT>
begin 644 image01.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1"617AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0=NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %!I;F<@4F%W
M<V]N   !ZAP !P  " P   AH     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                  !0 &D ;@!G "  4@!A '< <P!O &X   #_X0ID:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G:6X])^^[
MOR<@:60])U<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(^/')D9CI21$8@>&UL;G,Z<F1F
M/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C
M(CX\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB
M83-D+3$Q9&$M860S,2UD,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O
M<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(O/CQR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2)U=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W
M-3$X,F8Q8B(@>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT
M<R\Q+C$O(CX\9&,Z8W)E871O<CX\<F1F.E-E<2!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z
M;&D^4&EN9R!287=S;VX\+W)D9CIL:3X\+W)D9CI397$^#0H)"0D\+V1C.F-R
M96%T;W(^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO>#IX;7!M971A
M/@T*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" \/WAP86-K970@96YD/2=W)S\^
M_]L 0P '!04&!00'!@4&" <'" H1"PH)"0H5#Q ,$1@5&AD8%1@7&QXG(1L=
M)1T7&"(N(B4H*2LL*QH@+S,O*C(G*BLJ_]L 0P$'" @*"0H4"PL4*AP8'"HJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ_\  $0@ XP$= P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           !
M @,$!08'" D*"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-1
M80<B<10R@9&A""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$
M149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8
MF9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;G
MZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*
M"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"
MD:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-4
M55976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6F
MIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V
M]_CY^O_:  P# 0 "$0,1 #\ ^D:*\-^-_C;Q'X9\6V%IH6JRV4$EB)'1%4Y;
MS'&>0>P%>;?\+:\=?]#%<_\ ?"?_ !-;QH2DKW,W42=CZ[HKY$_X6UXY_P"A
MBN?^^$_^)JQ;?&;QY;=-<,H]);>)O_9:KZO+N+VD3ZSHKQ'P)\?/MU]%IWC*
M&&V,A"I?P_*@/^VIZ?[PX'ICFO;00R@J001D$'K6$X2@[,T33V%HKP'XO^)/
M&W@[QB?[/UNYBTN^3S;8!5(0C =,E>QY^C"N2T+XR>++'7[*XU;5Y[RQ24?:
M(&1/G3HW0=<<CW%:JA*4;IDN:3L?5=%1V\\5U;17%O(LD,R!XW4Y#*1D$?A4
ME8%A17GOQC\;S>#_  BB:9/Y.J7\GEV[@ F-5P7?GCI@?\"KP7_A;7CG_H8K
MC_OA/_B:VA1E-71$IJ+L?7E%<A\,1KLG@>UO?%%[+=7U[^_'F@ QQG[BX ';
MG\:Z^LI*SL6M0HKQ+XW?$36/#^OV&D^'-0:S=(#-<M&%)8L<*IR#C 4G_@5>
M8?\ "V?'7_0Q7'_?"?\ Q-;1H2DKD.HD['UY16)X-UP>)/!FEZL&W-<VZF0X
MQ^\'#_\ CP-;=8M6=F6%%%?)^K_%7QM!K=]##X@N$CCN9$10B< ,0!]VKITW
M/8F4E'<^L**^1/\ A;7CG_H8KG_OA/\ XFC_ (6UXZ!S_P )%<?]\)_\36OU
M>7<CVJ/KNBOE:Q^.?CFTEC:;4(+Q%/,<]J@##T)4 _K7MGPZ^*NF^.T:T>/[
M#JT:;GMF;*R#NR'N/;J/?K6<Z,XJ[*4TSO:**\;^.GC#7_"]]HR:!J4EDL\<
MIE"*IW$%<=0?4U$(N<K(INRN>R45\P>"OB9XQU+QUHEE?:[/-;7%[%'+&R)A
ME+ $=*^GZJI3<'9BC)26@45B^*_%>F>#]"DU/5Y=J+\L<:_?F?LJCN?Y5\Y^
M)OC?XKUR>1=.N!H]F3\D5M_K,>\AYS],"G"E*>P2DH[GU-17Q--XEUVXF,L^
MM:A)(3G<UTY/\ZW=#^*OC+095,&M3W40QF&\/G*1Z?-R/P(K5X9VT9'M4?7E
M5[Z^M=-L9KS4)X[>VA4O)+(V%4>YKCOAS\3].\>VK0^7]CU6!-TUJ3D,.F]#
MW&3TZC/XU'\0(H]5\7^#M!U YTN\NIYKB(_=F:&,-&A]02>G>L.1\W*S2^ET
M+_PMW0MGVD:=KATW=C^TQIS_ &?'][=UQ^%=GI^H6FJZ?#?:=<1W-K.N^.6-
MLJPKP31]8UR;6=%A6]UB![S6)(5NKK4-UC+$DC!H1%SSMPH'&>U>A>#$&B>-
M_&&B:4G_ !+;>>WN(H%^[ \T9:15]!D X[5I.FEL)-GF7[1O_(]:;_V#1_Z-
M>O-?#F@W/B?Q#::/8/%'<73%4:8D*, GG )[>E>E?M&_\CUIO_8-'_HUZY7X
M1?\ )6-"_P"NK_\ HMJZH.U*YA+69TA_9V\6@<7VDGV\Z3_XBL36_@SXTT2V
M>X?3DO84Y9K*3S"!Z[>&/X"OK"BN98B9K[.)\)U]"_ 'QK-J6GW'AK4IO,EL
M4$MHSG+&+."OOM.,>S>U<5\=?",'A[Q=%J5A$L5KJRM(448"S*1OP/?*GZDU
MRGPZUH^'_B'H]]NVQ_:%BE/^P_R-^AS^%=,DJM.Z,HWA*Q]+_$[P>OC/P5<V
M<2 WT \^S;'/F ?=SZ,,C\0>U?(9!5B&!!!P0>U?==?+WQM\&?\ "->,#J5I
M'MT_5BTJA1Q'+_&OXD[A]3Z5AAY_99I4CU/1_@#XM.K>%YM!NY-USI9!AR>6
MA8\?]\G(^A6O6Z^-? ?BF3P=XRLM67<8%;R[E%_CB;AA]1U'N!7T/\6_&T7A
M[X>M)I\X:ZU=/)M'0_P,N6D'T4\'U84JM-\^G4<)>[J>#?%'Q8?%_CN[NHG+
M65L?LUH,\;%/WO\ @1R?Q'I4OPI\'_\ "8>.+>&XCW6%GBYN\]&4'A/^!' ^
MF:XFOJ_X/^#/^$1\%1O=Q[=1U'%Q<Y'*#'R)^ /YDUO4DJ<+(SBN:5V=Z  ,
M 8 Z 4,P526(  R2>U+7(?%/6_[!^&NKW*.$FEA^SQ9ZEI#MX]P"3^%<$5=V
M.AZ:GR_XVUT^)?&VJZKN+1SW#>3GM&ORI_XZ!6%2=*ZSQOX-E\)6^@R2 _\
M$QTY)Y"1]V7.67\ RUZFBLCDU>IZQ^SIX@\_1=2T&9_GM91<PJ3R4?AL>P8#
M_OJO::^2/A%KAT+XFZ6[/MANW-I+DX!#\#/_  +:?PKZWKAKQM._<Z*;O$*^
M(=<_Y&+4O^ON7_T,U]O5\0ZY_P C%J7_ %]R_P#H9K3#;LBKL=!X(^&VK^/8
M;R71[BSA%FR+(+EV7.X$C&%/I732_L\^+XUREUI4A]%G<?S2NI_9K_Y!_B'_
M *[0?^@O7M]%2M*,VD$8)JY\:^)O ?B3PAAM<TV2&!CA;A"'B)]-PX!]C@UB
M6-]=:9?P7MA.\%S X>*5#@J17VQJ^DVFN:/=:9J4?F6MU&8Y%]CW'N.H/J*^
M+]=TF70?$%_I-P0TEG.\)8=&P< _B.:UI5/:*S)G'EU1]=^!/%47C'P?9ZN@
M5)779<1K_!*O##Z=Q[$5Y'^TG_R$M _ZY3?S2IOV<-:;S-8T.1B5PMW$,\+_
M  /^?R?E4/[2?_(2T#_KE-_-*QA'EK6+D[PN>:?#S_DI7AW_ +",/_H8K['D
M=8HV>1E1%!+,QP !W-?''P\_Y*5X=_[",/\ Z&*^C?C-KK:%\,;\PL5FOBMG
M&1VW_>_\<#4ZZYII"INT6SY[^)'C.X\:^+KB[,A-A QBLHNRQ@_>QZMU/Y=J
MRO#7A;5_%NJC3]"M3/-C<[$X2-?[S-T _GVK'KZX^%/A.'PIX#LT\M1>WJ+<
MW3XY+,,A?^ @@8]<^M;5)*E'0B*YWJ>8Q?LW:D;/=/XAM4N<?<2W9D_[Z)!_
M2O./&'@76_!%^(-:MQY4A/DW41W12_0]C['!K[)KG?'WAV/Q1X'U+36B$DS0
MM);\9*RJ,H1^/'T)KGA7ES>\:NFK:'R)HFLWGA_6K75=,E,5S:R!T(/!]5/J
M"."/0U]97EAIWQ+\$V%Y;SR6CR!+RRNX3^\M)AW'N#D$=^?K7SYH?P7\::UM
M9M-&FQ'_ ):7[^7C_@(RWZ5]"?#?PK?^#/!\>CZG>Q7<D<KNC1 A45N=HSR>
M<GMUJZ\HZ-/4FFFMSEF\)^-VTI-";3_"C6L<_P!H2^VR@K+DGSA'T$F23_=R
M?2NV\)>%8/"NER0+<27MY<RF>\O9O]9<2GJQ]!Z#M6]17-*;:L:V/G#]HW_D
M>M-_[!H_]&O7*_"+_DK&A?\ 75__ $6U=5^T;_R/6F_]@T?^C7KE?A%_R5C0
MO^NK_P#HMJ[8_P +Y&#^,^N:***\\Z#R#]HRT63P5IMWCYH;\(#[,C9_]!%?
M.:.8Y%=>"I##\*^EOVAR!\.+;/4ZE'C_ +XDKYG/2O0H? <]3XC[GLY_M5C!
M<?\ /6-7_,9KG?B+X47QEX)O-,55^U >=:L?X95Y'Y\K]&K9T(%?#NG!NHM8
M@?\ O@5?-<%^5W1T;GPI)&\4C1RJ4="596&"".H-7]2US4-6L].M;^<RQ:;!
M]GMU/\*;B?ZX^@ [5Z+\>?""Z'XKCUJS0+:ZMN:10.%G'WO^^@0?KNKRJO3C
M)22D<C33L=Y\'_"!\5^.H&N(]]AIV+FYW#*L0?D3\3V] :^L*XKX5>#T\(>"
M+:&2,"_O +B[;'.XCA/^ C ^N?6NU%<%:?/(Z(1L@KP;]HWQ 3)I7AZ)N #>
M3@'ZJG_L_P"8KWDU\<?$37CXD^(&K:@K[HC.8H3_ -,T^5?S S^-7AXWG?L*
MH[1(/ ^A?\))XXTK2BI:.:X4RX_YYK\S_P#CH->^?'S01J?P^748ES+I4ZR?
M]LV^5A^94_A7$?LZ:,+CQ+J>KR1AEL[=88V/9W.3C_@*D?C7OFL:9#K.BWFF
MW(S%=P/"W&<!AC-55G:HO(4(^Z?$4<CPRI)$Q5T8,K#L1R#7VEX2UQ?$GA'3
M-73&;NW5W ' ?HP_!@17Q?<0/:W4MO,"LD+M&X(Z$'!KZ"_9UU\W7A_4="F?
M+64PGA!/\#]0/8,,_P# JTQ$;QOV)INSL>S5\0ZY_P C%J7_ %]R_P#H9K[>
MKXAUS_D8M2_Z^Y?_ $,U&&W8ZNQ[?^S7_P @_P 0_P#7:#_T%Z]OKQ#]FO\
MY!_B'_KM!_Z"]>WUE6_B,N'PH*^4?C;;+;_%G4R@P)4AD./4QJ#^HKZNKY9^
M.Y!^*MT!VMH0?^^:K#_&*I\(_P" MTT'Q2AB4X%Q:S1M[@ -_P"RUTO[2?\
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M_"%^*/\ H7=5_P# .3_"OKZBCZNNX?VI/^4^-M0T'5])B675-+O+*-VVJ]Q
MR!CZ D=:SZ]__:#_ .14TO\ Z_?_ &1J\ KFG'EE8]3#5G6IJ;0^**2XF2&!
M&DED8*B(,EB>  .YK8_X0OQ1_P!"[JO_ (!R?X5'X3_Y'31?^O\ @_\ 1@K[
M"JZ5/GN88O%O#M)*]SY!_P"$+\4?]"[JO_@')_A1_P (7XH_Z%W5?_ .3_"O
MKZBMOJZ[G%_:D_Y3Y!_X0OQ1_P!"[JO_ (!R?X5#=^%]>L+5[F^T74+:WC&7
MEEMG55YQR2,#FOL2N-^+7_)*]:_ZYQ_^C4J94$HMW+IYC*<U'EW9\L444'H:
MY3V39C\'^)98UDB\/ZFZ. RLMHY# ]"#BG?\(7XH_P"A=U7_ , Y/\*^K?#W
M_(LZ7_UYQ?\ H K1KK6'35[GB2S.2;7*?(/_  A?BC_H7=5_\ Y/\*/^$+\4
M?]"[JO\ X!R?X5]?44_JZ[B_M2?\I\@_\(7XH_Z%W5?_  #D_P */^$+\4?]
M"[JO_@')_A7U]11]77</[4G_ "GR#_PA?BC_ *%W5?\ P#D_PH_X0OQ1_P!"
M[JO_ (!R?X5]?44?5UW#^U)_RGR#_P (7XH_Z%W5?_ .3_"C_A"_%'_0NZK_
M . <G^%?7U%'U==P_M2?\I\@_P#"%^*/^A=U7_P#D_PH_P"$+\4?]"[JO_@'
M)_A7U]11]77</[4G_*?//P@\-ZYIGQ%MKG4='OK2!8)099[=T4$KQR17T-11
M6U.'(K'!B*[KSYFK!1116ASA1110 4444 %%%% !1110 4444 >2_M!_\BII
M?_7[_P"R-7@%>_\ [0?_ "*FE_\ 7[_[(U> 5Y];^(SZ7+_]W7S-?PG_ ,CI
MHO\ U_P?^C!7V%7Q[X3_ .1TT7_K_@_]&"OL*ML/U.+-/BB%%%%=1XX5QOQ:
M_P"25ZU_USC_ /1J5V5<;\6O^25ZU_USC_\ 1J5%3X&;8?\ C0]5^9\L4AZ&
MEI#T->8?6GV3X>_Y%G2_^O.+_P! %:-9WA[_ )%G2_\ KSB_] %:->I'X4?'
MS^)A1115$!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 >2_M!_\ (J:7_P!?O_LC5X!7O_[0?_(J:7_U^_\ LC5X!7GUOXC/
MI<O_ -W7S-?PG_R.FB_]?\'_ *,%?85?'OA/_D=-%_Z_X/\ T8*^PJVP_4XL
MT^*(4445U'CA7&_%K_DE>M?]<X__ $:E=E7&_%K_ ))7K7_7./\ ]&I45/@9
MMA_XT/5?F?+%(>AI:0]#7F'UI]D^'O\ D6=+_P"O.+_T 5HUG>'O^19TO_KS
MB_\ 0!6C7J1^%'Q\_B844451 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'DO[0?_(J:7_U^_\ LC5X!7O_ .T'_P BII?_
M %^_^R-7@%>?6_B,^ER__=U\S7\)_P#(Z:+_ -?\'_HP5]A5\>^$_P#D=-%_
MZ_X/_1@K["K;#]3BS3XHA11174>.%<;\6O\ DE>M?]<X_P#T:E=E7&_%K_DE
M>M?]<X__ $:E14^!FV'_ (T/5?F?+%(>AI:0]#7F'UI]D^'O^19TO_KSB_\
M0!6C6=X>_P"19TO_ *\XO_0!6C7J1^%'Q\_B844451 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DO[0?_ "*FE_\ 7[_[
M(U> 5[_^T'_R*FE_]?O_ +(U> 5Y];^(SZ7+_P#=U\S7\)_\CIHO_7_!_P"C
M!7V%7Q[X3_Y'31?^O^#_ -&"OL*ML/U.+-/BB%%%%=1XX5QOQ:_Y)7K7_7./
M_P!&I795QOQ:_P"25ZU_USC_ /1J5%3X&;8?^-#U7YGRQ2'H:6D/0UYA]:?9
M/A[_ )%G2_\ KSB_] %:-9WA[_D6=+_Z\XO_ $ 5HUZD?A1\?/XF%%%%40%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y+^
MT'_R*FE_]?O_ +(U> 5[_P#M!_\ (J:7_P!?O_LC5X!7GUOXC/I<O_W=?,U_
M"?\ R.FB_P#7_!_Z,%?85?'OA/\ Y'31?^O^#_T8*^PJVP_4XLT^*(4445U'
MCA7&_%K_ ))7K7_7./\ ]&I795QOQ:_Y)7K7_7./_P!&I45/@9MA_P"-#U7Y
MGRQ2'H:6D/0UYA]:?9/A[_D6=+_Z\XO_ $ 5HUG>'O\ D6=+_P"O.+_T 5HU
MZD?A1\?/XF%%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!Y+^T'_P BII?_ %^_^R-7@%>__M!_\BII?_7[_P"R-7@%
M>?6_B,^ER_\ W=?,U_"?_(Z:+_U_P?\ HP5]A5\>^$_^1TT7_K_@_P#1@K["
MK;#]3BS3XHA11174>.%<;\6O^25ZU_USC_\ 1J5V5<;\6O\ DE>M?]<X_P#T
M:E14^!FV'_C0]5^9\L4AZ&EI#T->8?6GV3X>_P"19TO_ *\XO_0!6C6=X>_Y
M%G2_^O.+_P! %:->I'X4?'S^)A1115$!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 >2_M!?\BII?_7[_P"R-7@%?5?Q#\#G
MQWI-K9+?_8?L\_F[S%YF[Y2,8R/6O/O^&=G_ .AE7_P"_P#LZXJM.<IMI'N8
M/%4:=%1F[,\L\)_\CIHO_7_!_P"C!7V%7CFD? 5]+UJROSXA$OV6X2;9]CQN
MVL#C._CI7L=:T82C>YRX^M3JRBX.X4445T'FA7&_%K_DE>M?]<X__1J5V58W
MB[0#XH\*WNC"X^S&Z55\W9OVX8-TR,]/6IFFXM(UHR4:D9/9-'Q_2'H:]K_X
M9W?_ *&5?_ +_P"SH/[.SX_Y&5?_  "_^SK@]C/L?1?7L/\ S?F>O>'O^19T
MO_KSB_\ 0!6C5;3K3[!I=K:;]_V>%(MV,;MJ@9Q^%6:]".B1\U)WDV@HHHID
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
